AJP - Endocrinology and Metabolism, Vol 264, Issue 6 E943-E950, Copyright © 1993 by American Physiological Society

ARTICLES

Response to intravenous injections of amylin and glucagon in fasted, fed, and hypoglycemic rats

A. A. Young, G. J. Cooper, P. Carlo, T. J. Rink and M. W. Wang
Department of Physiology, Amylin Pharmaceuticals, San Diego, California 92121.

The actions of intravenous glucagon and amylin, a newly discovered hyperglycemic pancreatic islet hormone, have been compared in 20-h fasted and fed, lightly anesthetized rats, and in rats made hypoglycemic with an insulin infusion. In fasted animals, amylin (75 nmol/kg) was more effective than glucagon (90 nmol/kg) in increasing plasma glucose (glucose increment 4.55 vs. 1.71 mM, P < 0.001). Amylin elicited a marked increase in plasma lactate, as previously reported, whereas glucagon did not alter plasma lactate. In fed animals, glucagon elicited twice as much increase in plasma glucose as did amylin; amylin again elicited a marked lactate increase that was greater (increment 1.45 vs. 0.97 mM, P < 0.05) and more prolonged than in the fasted state, whereas glucagon was without effect on lactate levels. These findings are consistent with glucagon's known action to promote hyperglycemia from hepatic glycogenolysis and amylin's demonstrated action to promote muscle glycogenolysis and increase lactate supply to the liver. Infusions of sodium lactate that produced plasma lactate increments similar to those evoked by 75 nmol/kg amylin evoked patterns of glucose response in fasted and fed rats similar to those evoked by amylin. Thus increased lactate supply to the liver may account for amylin's hyperglycemic effects. Amylin and glucagon could each restore plasma glucose to control levels in fasted animals made hypoglycemic by insulin infusion (plasma glucose reduced to 3.3 mM). A bolus of 75 nmol/kg amylin was more effective than 180 nmol/kg glucagon, restoring basal glucose levels for > 3 h, whereas glucagon restored it for < 1 h.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				G. Jiang and B. B. Zhang Glucagon and regulation of glucose metabolism Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E671 - E678. [Abstract] [Full Text] [PDF]

				J.-M. Ye, M. Lim-Fraser, G. J. Cooney, G. J. S. Cooper, M. A. Iglesias, D. G. Watson, B. Choong, and E. W. Kraegen Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance Am J Physiol Endocrinol Metab, April 1, 2001; 280(4): E562 - E569. [Abstract] [Full Text] [PDF]

				J. H. James, K. R. Wagner, J.-K. King, R. E. Leffler, R. K. Upputuri, A. Balasubramaniam, L. A. Friend, D. A. Shelly, R. J. Paul, and J. E. Fischer Stimulation of both aerobic glycolysis and Na+-K+-ATPase activity in skeletal muscle by epinephrine or amylin Am J Physiol Endocrinol Metab, July 1, 1999; 277(1): E176 - E186. [Abstract] [Full Text] [PDF]

				A. L. Castle, C.-H. Kuo, D.-H. Han, and J. L. Ivy Amylin-mediated inhibition of insulin-stimulated glucose transport in skeletal muscle Am J Physiol Endocrinol Metab, September 1, 1998; 275(3): E531 - E536. [Abstract] [Full Text] [PDF]

				A. L. Castle, C.-H. Kuo, and J. L. Ivy Amylin influences insulin-stimulated glucose metabolism by two independent mechanisms Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E6 - E12. [Abstract] [Full Text] [PDF]

				M. Hettiarachchi, S. Chalkley, S. M. Furler, Y.-S. Choong, M. Heller, G. J. S. Cooper, and E. W. Kraegen Rat amylin-(8---37) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats Am J Physiol Endocrinol Metab, November 1, 1997; 273(5): E859 - E867. [Abstract] [Full Text] [PDF]